Organon Corp (OGN) - Forward P/S Multiple

Public company logo of Organon (OGN)

Organon & Co. (OGN) relies on a global network of plants and unique patents in the women's health sector. The scalable business of this Merck spin-off serves as a cash cow, generating strong cash flow through low-cost contraceptive production. The projected P/S trend captures the objective value of the assets, where the indicator stands at 0.10. Risks are linked to the debt load and dependence on sales of a key implant.

Organon - OGN Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

OGN (Organon Pharma): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Organon|OGN - Fair Value Consensus
- market capitalization indicators:
Market Capitalization Organon Pharma|OGN - Full Takeover Company Value
- issuer book value statistics:
Book Value per Share Organon|OGN - Book Capitalization|Market Value to Book Value Ratio organon.com|OGN - Total Business Assets
- debt and liquidity details:
Debt to Equity Organon & Co.|OGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Organon & Co.|OGN - Company Aggregate Debt|Debt to Book Value Organon Pharma|OGN - Company Long-Term Loans and Borrowings|Company Short-Term Indebtedness Organon|Quick Liquidity Indicator organon.com
- financial results and valuation multiples details:
OGN - Final Profit|Projected Future Earnings Organon & Co.|OGN - Price to Earnings Ratio|Future Price to Earnings Organon Corp|OGN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Organon Pharma|OGN - Operating income before deduction of amortization|Earnings per share for the last twelve months Organon|OGN - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth organon.com|OGN - Net earnings per share change in current year|Net earnings per share growth forecast for next year Organon & Co.
- total revenue and sales volume data:
OGN - Company Sales Volume|Company Projected Revenue Organon|OGN - Price-to-Sales Ratio|Forward P/S Multiple Organon Pharma
Fundamental company valuation:Organon (OGN)
Original product of Organon & Co.

Stable sales of biosimilars and women's health products from Organon & Co. (OGN) create a revenue foundation that the market values while accounting for patent risks. The forward P/S metric correlates current market capitalization with projected sales volume, allowing investors to determine the degree of business undervaluation and identify phases of hidden accumulation or asset liquidation through the analysis of this curve.

Key competitors

Price-to-Projected Revenue Ratio Daré Bioscience DARE|Forward Price to Sales TXMD|Palatin - Forward P/S Multiple